Kane Biotech (TSE:KNE) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kane Biotech has announced that BioStem Technologies will acquire exclusive U.S. distribution rights for its revyve Antimicrobial Wound Gel from ProgenaCare Global, marking a strategic move to enhance BioStem’s wound care portfolio. This acquisition is expected to significantly boost the market presence of revyve products in the U.S., leveraging BioStem’s strong growth and commercial infrastructure in the sector.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue